The Analyst Verdict: Corcept Therapeutics In The Eyes Of 4 Experts
In the preceding three months, 4 analysts have released ratings for Corcept Therapeutics (NASDAQ:CORT), presenting a wide array…
Mid-Cap Corcept Therapeutics Reveals Data From Hormonal Disorder Study, FDA Application Submission Expected This Quarter
Insights from Corcept Therapeutics' Phase 3 GRACE trial results for endogenous Cushing's syndrome. Discover rapid improvements in hypertension and hyperglycemia without adverse effects. Join us for the upcoming medical conference in June.
Corcept Announces Results From Open-Label Portion Of Pivotal Phase 3 GRACE Trial In Patients With Cushing’s Syndrome
Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by
Corcept Completes Enrollment In Phase 3 Gradient Trial Of Relacorilant In Patients With Adrenal Cushing’s Syndrome
Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by
What’s Going On With Stress Hormone Modulator-Focused Corcept Therapeutics’ Stock Friday?
Findings of Corcept Therapeutics' CATALYST study on Cushing's syndrome & difficult-to-control type 2 diabetes.
Corcept Announces Preliminary Results From Prevalence Phase Of CATALYST Clinical Trial; Of The First 700 Patients Enrolled In Catalyst, 24% Were Identified As Having Hypercortisolism
Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by
Recap: Corcept Therapeutics Q4 Earnings
Corcept Therapeutics (NASDAQ:CORT) reported its Q4 earnings results on Thursday, February 15, 2024 at 04:05 PM. Here’s what…
Earnings Scheduled For February 15, 2024
Companies Reporting Before The Bell
• Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on revenue of $188.59 million.
Earnings Preview: Corcept Therapeutics
Corcept Therapeutics (NASDAQ:CORT) is set to give its latest quarterly earnings report on Thursday, 2024-02-15. Here’s what investors…
Archer-Daniels-Midland, B. Riley Financial And Other Big Stocks Moving Lower In Monday’s Pre-Market Session
U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 100 points on Monday.
Shares of Archer-Daniels-Midland Company (NYSE: ADM) fell sharply in today’s pre-market trading after the company named Ismael Roig as Interim Chief Financial Officer.